A senior health official has underscored the growing challenges faced by the healthcare system due to sanctions, revealing a severe strain on the importation of essential medications. According to the statement, the restrictive measures have significantly hampered efforts to procure vital drugs and medical supplies, impacting treatment for patients who rely on imported pharmaceuticals.
The official emphasized that while some domestic production capabilities exist, the limited range and specialized nature of certain drugs mean international imports remain critical. “These sanctions disrupt the global supply chain and create severe logistical hurdles, delaying or preventing the arrival of life-saving medications,” they noted.
The healthcare system’s reliance on foreign-sourced medicines, particularly for advanced treatments and rare diseases, has brought into focus the vulnerability faced under geopolitical pressures. Patients with chronic conditions and those requiring specialized care, such as cancer therapies, have been among the most affected.
Efforts to mitigate these challenges have included partnerships with non-sanctioned entities and exploring alternative import routes. However, these measures often come at higher costs and extended lead times, placing additional strain on the national budget and delaying patient treatment.
“The impact on public health is undeniable. Prolonged sanctions affect not only the availability but also the affordability of crucial medicines, creating disparities in access to healthcare,” the official added. The call for international cooperation and dialogue was reiterated to ensure humanitarian exemptions that safeguard public health services.
As the situation unfolds, healthcare advocates are urging global institutions and policymakers to consider the humanitarian implications of economic sanctions and their repercussions on vulnerable patient communities.
